EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Oncogenic Pathways and Targeted Therapies in Ovarian Cancer

Carolina Lliberos, Gary Richardson, Antonella Papa iD

Biomolecules · 15.05.2024 · 14 (5) · 585

DOI: 10.3390/biom14050585 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 15.05.2024. Verfasst von Carolina Lliberos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Program, Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Austr…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Molecular Targeted Therapy, Signal Transduction. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Philantropic funding donated to Cabrini Research, Victorian Cancer Agency, philanthropic funding donated to Cabrini Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epithelial ovarian cancer (EOC) is one of the most aggressive forms of gynaecological malignancies. Survival rates for women diagnosed with OC remain poor as most patients are diagnosed with advanced disease. Debulking surgery and platinum-based therapies are the current mainstay for OC treatment. However, and despite achieving initial remission, a significant portion of patients will relapse because of innate and acquired resistance, at which point the disease is considered incurable. In view of this, novel detection strategies and therapeutic approaches are needed to improve outcomes and survival of OC patients. In this review, we summarize our current knowledge of the genetic landscape and molecular pathways underpinning OC and its many subtypes. By examining therapeutic strategies explored in preclinical and clinical settings, we highlight the importance of decoding how single and convergent genetic alterations co-exist and drive OC progression and resistance to current treatments. We also propose that core signalling pathways such as the PI3K and MAPK pathways play critical roles in the origin of diverse OC subtypes and can become new targets in combination with known DNA damage repair pathways for the development of tailored and more effective anti-cancer treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsMolecular Targeted TherapySignal TransductionHumansFemaleCarcinoma, Ovarian EpithelialAntineoplastic AgentsAnimals

Stichwörter der Autor:innen

MAPKPI3Kovarian cancersignalling pathwaystargeted therapies

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Cancer Program, Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.
  • Neil Beauglehall Department of Medical Oncology Research, Cabrini Health, Malvern, VIC 3144, Australia.

ORCID-Profile: Antonella Papa

Förderung

  • Philantropic funding donated to Cabrini Research
  • Victorian Cancer Agency
  • philanthropic funding donated to Cabrini Research
  • Victorian Cancer Agency Mid-Career Research Fellowships

Zitieren

APA

Lliberos, C., Richardson, G., & Papa, A. (2024). Oncogenic Pathways and Targeted Therapies in Ovarian Cancer. Biomolecules, 14(5), 585. https://doi.org/10.3390/biom14050585

Vancouver

Lliberos C, Richardson G, Papa A. Oncogenic Pathways and Targeted Therapies in Ovarian Cancer. Biomolecules. 2024;14(5):585. doi:10.3390/biom14050585

BibTeX
@article{Lliberos2024,
  author = {Lliberos, Carolina and Richardson, Gary and Papa, Antonella},
  title = {Oncogenic Pathways and Targeted Therapies in Ovarian Cancer},
  journal = {Biomolecules},
  year = {2024},
  volume = {14},
  number = {5},
  pages = {585},
  doi = {10.3390/biom14050585}
}
Kostenlos starten →